Answers are grounded in this paper and cite their sources.
Breast cancer (BC) is a biologically heterogeneous disease that evolves through complex interactions between genetic, epigenetic, hormonal and microenvironmental factors. For pathologists, understanding breast carcinogenesis is fundamental to interpreting the morphological and molecular features that underpin tumour classification, prognostic assessment, biomarker evaluation and therapeutic stratification. Rather than a linear process, breast carcinogenesis follows branching evolutionary pathways driven by successive molecular alterations, clonal selection and tumour-microenvironment interactions, resulting in the diverse histological phenotypes encountered in routine practice. These biological processes are reflected morphologically in the spectrum of precursor lesions, in situ neoplasia and invasive carcinomas, while key molecular drivers, including oestrogen receptor signalling, HER2 amplification, PI3K/AKT/mTOR activation, TP53 dysfunction and homologous recombination deficiency, determine tumour behaviour and therapeutic vulnerabilities. Understanding these pathways also provides the biological rationale for contemporary targeted therapies, including endocrine treatment, HER2-directed agents, PARP inhibitors and other precision therapies. This narrative review integrates current knowledge of breast carcinogenesis with diagnostic pathology, illustrating how tumour evolution shapes morphology, molecular phenotype and clinical behaviour. We propose that carcinogenesis should complement morphology as an organising framework for breast tumour classification, enabling pathologists to interpret histological features within their biological context and strengthening diagnostic accuracy, biomarker interpretation and precision medicine.
No takes yet. Share an insight, caveat, or question.
Rakha et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: